Byrne, F.L.; Olzomer, E.M.; Lolies, N.; Hoehn, K.L.; Wegner, M.-S. Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma. Int. J. Mol. Sci.2022, 23, 4477.
Byrne, F.L.; Olzomer, E.M.; Lolies, N.; Hoehn, K.L.; Wegner, M.-S. Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2022, 23, 4477.
Hepatocellular carcinoma (HCC) is the most frequent type of primary liver cancer. Low numbers of HCC patients being suitable for liver resection or transplantation and multidrug resistance development during pharmacotherapy leads to high death rates for HCC patients. Understanding the molecular mechanisms of HCC aetiology contributes to development of novel therapeutic strategies for prevention and treatment of HCC. UDP-glucose ceramide glycosyltransferase (UGCG), a key enzyme in glycosphingolipid metabolism, generates glucosylceramide (GlcCer), which is the precursor for all glycosphingolipids (GSLs). Since UGCG gene expression is altered in 0.8 % of HCC tumors, GSLs may play a role in cellular processes in liver cancer cells. Here, we discuss current literature about GSLs and their abundance in normal liver cells, Gaucher disease and HCC. Furthermore, we review the involvement of UGCG/GlcCer in multidrug resistance development, globosides as a potential prognostic marker for HCC, gangliosides as a potential liver cancer stem cell marker, and the role of sulfatides in tumor metastasis. Only a limited number of molecular mechanisms executed by GSLs in HCC are known, which we summarize here briefly.
glycolysis; GEMs; oxidative phosphorylation; UGCG; glucosylceramide; normal liver cells; gangliosides; lacto/neo-lacto series GSLs; sulfatides
MEDICINE & PHARMACOLOGY, Oncology & Oncogenics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.